Ceapro Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRPOF research report →
Price Chart
About the company
Operating as a biotechnology enterprise, Ceapro Inc. is dedicated to pioneering and bringing to market health and wellness offerings, alongside their underlying technologies, which are all predicated on plant-derived compounds. Its commercial reach extends across the United States, Germany, China, Canada, and various other global markets.
- CEO
- Gilles R. Gagnon
- IPO
- 2021
- HQ
- Edmonton, AB, CA
Get TickerSpark's AI analysis on CRPOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.31M
- P/E
- -3.74
- PEG
- 0.04
- P/S
- 0.07
- P/B
- 0.63
- EV/EBITDA
- 1.54
- Div Yield
- 0.00%
- Gross Margin
- 36.99%
- Op Margin
- -64.93%
- Net Margin
- -48.89%
- ROE
- -15.66%
- ROIC
- -16.57%
Latest fiscal year · YoY change
- Revenue
- $9.63M-48.9%
- Gross Profit
- $3.56M-67.7%
- Op Income
- $-6,255,360
- Net Income
- $-4,709,893-207.1%
- EPS
- $-0.06-206.7%
- OCF Growth
- -154.6%
- FCF Growth
- -173.1%
- 52W High
- $0.40
- 52W Low
- $0.12
- 50D MA
- $0.18
- 200D MA
- $0.20
- Beta
- 1.38
- RSI (14)
- 25
- Avg Volume
- 6.12K
No earnings-call transcripts are available for CRPOF yet.
- Free Float
- 97.3%
- Shares Outstanding
- 78.29M
- Float Shares
- 76.19M
Our CRPOF coverage
Recent articles, reports, and earnings notes.
No research on CRPOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRPOF report →Analyzing Ceapro (OTCMKTS:CRPOF) and ProMetic Life Sciences (OTCMKTS:PFSCF)
defenseworld.net · Feb 2
Head to Head Comparison: Synaptogenix (NASDAQ:TAOX) versus Ceapro (OTCMKTS:CRPOF)
defenseworld.net · Dec 1
Ceapro (CVE:CZO) Shares Down 11.8% – Time to Sell?
defenseworld.net · Nov 1
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
prnewswire.com · Jun 7
Aeterna Zentaris and Ceapro Complete Merger Transaction
globenewswire.com · Jun 3
Aeterna Zentaris and Ceapro Complete Merger Transaction
globenewswire.com · Jun 3
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
globenewswire.com · May 29
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
globenewswire.com · May 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.